|
1
|
Engelman JA: Targeting PI3K signalling in
cancer: Opportunities, challenges and limitations. Nat Rev Cancer.
9:550–562. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Yuan TL and Cantley LC: PI3K pathway
alterations in cancer: Variations on a theme. Oncogene.
27:5497–5510. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Vanhaesebroeck B, Stephens L and Hawkins
P: PI3K signalling: The path to discovery and understanding. Nat
Rev Mol Cell Biol. 13:195–203. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Blachly JS and Baiocchi RA: Targeting
PI3-kinase (PI3K), AKT and mTOR axis in lymphoma. Br J Haematol.
167:19–32. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Foster FM, Traer CJ, Abraham SM and Fry
MJ: The phosphoinositide (PI) 3-kinase family. J Cell Sci.
116:3037–3040. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chen HC and Guan JL: Association of focal
adhesion kinase with its potential substrate phosphatidylinositol
3-kinase. Proc Natl Acad Sci USA. 91:10148–10152. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Izuhara K, Feldman RA, Greer P and Harada
N: Interleukin-4 induces association of the c-fes proto-oncogene
product with phosphatidylinositol-3 kinase. Blood. 88:3910–3918.
1996.PubMed/NCBI
|
|
8
|
Leslie NR and Downes CP: PTEN: The down
side of PI 3-kinase signalling. Cell Signal. 14:285–295. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Engelman JA, Luo J and Cantley LC: The
evolution of phosphatidylinositol 3-kinases as regulators of growth
and metabolism. Nat Rev Genet. 7:606–619. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sarbassov DD, Guertin DA, Ali SM and
Sabatini DM: Phosphorylation and regulation of Akt/PKB by the
rictor-mTOR complex. Science. 307:1098–1101. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kang S, Denley A, Vanhaesebroeck B and
Vogt PK: Oncogenic transformation induced by the p110beta, -gamma,
and -delta isoforms of class I phosphoinositide 3-kinase. Proc Natl
Acad Sci USA. 103:1289–1294. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chang HW, Aoki M, Fruman D, Auger KR,
Bellacosa A, Tsichlis PN, Cantley LC, Roberts TM and Vogt PK:
Transformation of chicken cells by the gene encoding the catalytic
subunit of PI 3-kinase. Science. 276:1848–1850. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Jiang BH, Zheng JZ, Aoki M and Vogt PK:
Phosphatidylinositol 3-kinase signaling mediates angiogenesis and
expression of vascular endothelial growth factor in endothelial
cells. Proc Natl Acad Sci USA. 97:1749–1753. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chang F, Lee JT, Navolanic PM, Steelman
LS, Shelton JG, Blalock WL, Franklin RA and McCubrey JA:
Involvement of PI3K/Akt pathway in cell cycle progression,
apoptosis, and neoplastic transformation: A target for cancer
chemotherapy. Leukemia. 17:590–603. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Courtney KD, Corcoran RB and Engelman JA:
The PI3K pathway as drug target in human cancer. J Clin Oncol.
28:1075–1083. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Rodon J, Dienstmann R, Serra V and
Tabernero J: Development of PI3K inhibitors: Lessons learned from
early clinical trials. Nat Rev Clin Oncol. 10:143–153. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mahadevan D and Fisher RI: Novel
therapeutics for aggressive non-Hodgkin's lymphoma. J Clin Oncol.
29:1876–1884. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Fang X, Zhou X and Wang X: Clinical
development of phosphatidylinositol 3-kinase inhibitors for
non-Hodgkin lymphoma. Biomark Res. 1:302013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Psyrri A, Papageorgiou S, Liakata E,
Scorilas A, Rontogianni D, Kontos CK, Argyriou P, Pectasides D,
Harhalakis N, Pappa V, et al: Phosphatidylinositol 3′-kinase
catalytic subunit alpha gene amplification contributes to the
pathogenesis of mantle cell lymphoma. Clin Cancer Res.
15:5724–5732. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Pfeifer M, Grau M, Lenze D, Wenzel SS,
Wolf A, Wollert-Wulf B, Dietze K, Nogai H, Storek B, Madle H, et
al: PTEN loss defines a PI3K/AKT pathway-dependent germinal center
subtype of diffuse large B-cell lymphoma. Proc Natl Acad Sci USA.
110:12420–12425. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Baohua Y, Xiaoyan Z, Tiecheng Z, Tao Q and
Daren S: Mutations of the PIK3CA gene in diffuse large B cell
lymphoma. Diagn Mol Pathol. 17:159–165. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhao MY, Auerbach A, D'Costa AM, Rapoport
AP, Burger AM, Sausville EA, Stass SA, Jiang F, Sands AM, Aguilera
N, et al: Phospho-p70S6K/p85S6K and cdc2/cdk1 are novel targets for
diffuse large B-cell lymphoma combination therapy. Clin Cancer Res.
15:1708–1720. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Choi MY and Kipps TJ: Inhibitors of B-cell
receptor signaling for patients with B-cell malignancies. Cancer J.
18:404–410. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Inabe K and Kurosaki T: Tyrosine
phosphorylation of B-cell adaptor for phosphoinositide 3-kinase is
required for Akt activation in response to CD19 engagement. Blood.
99:584–589. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Gupta M, Hendrickson AE, Yun SS, Han JJ,
Schneider PA, Koh BD, Stenson MJ, Wellik LE, Shing JC, Peterson KL,
et al: Dual mTORC1/mTORC2 inhibition diminishes Akt activation and
induces Puma-dependent apoptosis in lymphoid malignancies. Blood.
119:476–487. 2012. View Article : Google Scholar :
|
|
26
|
Bhende PM, Park SI, Lim MS, Dittmer DP and
Damania B: The dual PI3K/mTOR inhibitor, NVP-BEZ235, is efficacious
against follicular lymphoma. Leukemia. 24:1781–1784. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Uddin S, Hussain AR, Siraj AK, Manogaran
PS, Al-Jomah NA, Moorji A, Atizado V, Al-Dayel F, Belgaumi A,
El-Solh H, et al: Role of phosphatidylinositol 3′-kinase/AKT
pathway in diffuse large B-cell lymphoma survival. Blood.
108:4178–4186. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Mahadevan D, Chiorean EG, Harris WB, Von
Hoff DD, Stejskal-Barnett A, Qi W, Anthony SP, Younger AE, Rensvold
DM, Cordova F, et al: Phase I pharmacokinetic and pharmacodynamic
study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in
patients with advanced solid tumours and B-cell malignancies. Eur J
Cancer. 48:3319–3327. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Cheng H, Li C, Bailey S, Baxi SM, Goulet
L, Guo L, Hoffman J, Jiang Y, Johnson TO, Johnson TW, et al:
Discovery of the highly potent PI3K/mTOR dual inhibitor PF-04979064
through structure-based drug design. ACS Med Chem Lett. 4:91–97.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang FZ, Peng-Jiao, Yang NN, Chuang-Yuan,
Zhao YL, Liu QQ, Fei HR and Zhang JG: PF-04691502 triggers cell
cycle arrest, apoptosis and inhibits the angiogenesis in
hepatocellular carcinoma cells. Toxicol Lett. 220:150–156. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wong CH, Loong HH, Hui CW, Lau CP, Hui EP,
Ma BB and Chan AT: Preclinical evaluation of the PI3K-mTOR dual
inhibitor PF-04691502 as a novel therapeutic drug in nasopharyngeal
carcinoma. Invest New Drugs. 31:1399–1408. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Devereaux K, Dall'Armi C, Alcazar-Roman A,
Ogasawara Y, Zhou X, Wang F, Yamamoto A, De Camilli P and Di Paolo
G: Regulation of mammalian autophagy by class II and III PI
3-kinases through PI3P synthesis. PLoS One. 8:e764052013.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Carver BS, Chapinski C, Wongvipat J,
Hieronymus H, Chen Y, Chandarlapaty S, Arora VK, Le C, Koutcher J,
Scher H, et al: Reciprocal feedback regulation of PI3K and androgen
receptor signaling in PTEN-deficient prostate cancer. Cancer Cell.
19:575–586. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Fang DD, Zhang CC, Gu Y, Jani JP, Cao J,
Tsaparikos K, Yuan J, Thiel M, Jackson-Fisher A, Zong Q, et al:
Antitumor efficacy of the dual PI3K/mTOR inhibitor PF-04691502 in a
human xenograft tumor model derived from colorectal cancer stem
cells harboring a PIK3CA mutation. PLoS One. 8:e672582013.
View Article : Google Scholar :
|
|
35
|
Britten CD, Adjei AA, Millham R, Houk BE,
Borzillo G, Pierce K, Wainberg ZA and LoRusso PM: Phase I study of
PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and
mTOR, in patients with advanced cancer. Invest New Drugs.
32:510–517. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yuan J, Mehta PP, Yin MJ, Sun S, Zou A,
Chen J, Rafidi K, Feng Z, Nickel J, Engebretsen J, et al:
PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR
kinases with antitumor activity. Mol Cancer Ther. 10:2189–2199.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ikeda H, Hideshima T, Fulciniti M, Perrone
G, Miura N, Yasui H, Okawa Y, Kiziltepe T, Santo L, Vallet S, et
al: PI3K/p110{delta} is a novel therapeutic target in multiple
myeloma. Blood. 116:1460–1468. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lannutti BJ, Meadows SA, Herman SE,
Kashishian A, Steiner B, Johnson AJ, Byrd JC, Tyner JW, Loriaux MM,
Deininger M, et al: CAL-101, a p110delta selective
phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell
malignancies, inhibits PI3K signaling and cellular viability.
Blood. 117:591–594. 2011. View Article : Google Scholar
|
|
39
|
Herman SE, Gordon AL, Wagner AJ, Heerema
NA, Zhao W, Flynn JM, Jones J, Andritsos L, Puri KD, Lannutti BJ,
et al: Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows
promising preclinical activity in chronic lymphocytic leukemia by
antagonizing intrinsic and extrinsic cellular survival signals.
Blood. 116:2078–2088. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
García-García C, Ibrahim YH, Serra V,
Calvo MT, Guzmán M, Grueso J, Aura C, Pérez J, Jessen K, Liu Y, et
al: Dual mTORC1/2 and HER2 blockade results in antitumor activity
in preclinical models of breast cancer resistant to anti-HER2
therapy. Clin Cancer Res. 18:2603–2612. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Lou HZ, Weng XC, Pan HM, Pan Q, Sun P, Liu
LL and Chen B: The novel mTORC1/2 dual inhibitor INK-128 suppresses
survival and proliferation of primary and transformed human
pancreatic cancer cells. Biochem Biophys Res Commun. 450:973–978.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Kampa-Schittenhelm KM, Heinrich MC, Akmut
F, Rasp KH, Illing B, Döhner H, Döhner K and Schittenhelm MM: Cell
cycle-dependent activity of the novel dual PI3K-MTORC1/2 inhibitor
NVP-BGT226 in acute leukemia. Mol Cancer. 12:462013. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Suzuki E, Umezawa K and Bonavida B:
Rituximab inhibits the constitutively activated PI3K-Akt pathway in
B-NHL cell lines: Involvement in chemosensitization to drug-induced
apoptosis. Oncogene. 26:6184–6193. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Jabbour E, Ottmann OG, Deininger M and
Hochhaus A: Targeting the phosphoinositide 3-kinase pathway in
hematologic malignancies. Haematologica. 99:7–18. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Gao N, Zhang Z, Jiang BH and Shi X: Role
of PI3K/AKT/mTOR signaling in the cell cycle progression of human
prostate cancer. Biochem Biophys Res Commun. 310:1124–1132. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Ornelas IM, Silva TM, Fragel-Madeira L and
Ventura AL: Inhibition of PI3K/Akt pathway impairs G2/M transition
of cell cycle in late developing progenitors of the avian embryo
retina. PLoS One. 8:e535172013. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Wallin JJ, Edgar KA, Guan J, Berry M,
Prior WW, Lee L, Lesnick JD, Lewis C, Nonomiya J, Pang J, et al:
GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust
activity in cancer models driven by the PI3K pathway. Mol Cancer
Ther. 10:2426–2436. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Zou ZQ, Zhang LN, Wang F, Bellenger J,
Shen YZ and Zhang XH: The novel dual PI3K/mTOR inhibitor GDC-0941
synergizes with the MEK inhibitor U0126 in non-small cell lung
cancer cells. Mol Med Rep. 5:503–508. 2012.
|
|
49
|
Diehl JA, Cheng M, Roussel MF and Sherr
CJ: Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis
and subcellular localization. Genes Dev. 12:3499–3511. 1998.
View Article : Google Scholar : PubMed/NCBI
|
